Logo image of AKAN

AKANDA CORP (AKAN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AKAN - CA00971M5028 - Common Stock

0.9461 USD
-0.06 (-6.33%)
Last: 12/4/2025, 8:03:55 PM
1.24 USD
+0.29 (+31.06%)
Pre-Market: 12/5/2025, 7:05:10 AM
Fundamental Rating

1

AKAN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. AKAN may be in some trouble as it scores bad on both profitability and health. AKAN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AKAN has reported negative net income.
AKAN had a negative operating cash flow in the past year.
In the past 5 years AKAN always reported negative net income.
In the past 5 years AKAN always reported negative operating cash flow.
AKAN Yearly Net Income VS EBIT VS OCF VS FCFAKAN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

The Return On Assets of AKAN (-51.76%) is worse than 62.50% of its industry peers.
AKAN's Return On Equity of -95.78% is on the low side compared to the rest of the industry. AKAN is outperformed by 60.94% of its industry peers.
Industry RankSector Rank
ROA -51.76%
ROE -95.78%
ROIC N/A
ROA(3y)-148.92%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AKAN Yearly ROA, ROE, ROICAKAN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K

1.3 Margins

With a Gross Margin value of 24.91%, AKAN perfoms like the industry average, outperforming 53.65% of the companies in the same industry.
AKAN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 24.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AKAN Yearly Profit, Operating, Gross MarginsAKAN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

2

2. Health

2.1 Basic Checks

AKAN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AKAN has more shares outstanding
AKAN has a better debt/assets ratio than last year.
AKAN Yearly Shares OutstandingAKAN Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 100K 200K 300K
AKAN Yearly Total Debt VS Total AssetsAKAN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -11.56, we must say that AKAN is in the distress zone and has some risk of bankruptcy.
AKAN's Altman-Z score of -11.56 is on the low side compared to the rest of the industry. AKAN is outperformed by 75.52% of its industry peers.
A Debt/Equity ratio of 0.08 indicates that AKAN is not too dependend on debt financing.
AKAN has a Debt to Equity ratio (0.08) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z -11.56
ROIC/WACCN/A
WACC6.92%
AKAN Yearly LT Debt VS Equity VS FCFAKAN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

AKAN has a Current Ratio of 1.39. This is a normal value and indicates that AKAN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.39, AKAN is doing worse than 71.88% of the companies in the same industry.
AKAN has a Quick Ratio of 1.39. This is a normal value and indicates that AKAN is financially healthy and should not expect problems in meeting its short term obligations.
AKAN has a Quick ratio of 1.39. This is in the lower half of the industry: AKAN underperforms 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 1.39
AKAN Yearly Current Assets VS Current LiabilitesAKAN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

3

3. Growth

3.1 Past

AKAN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.31%, which is quite impressive.
The Revenue for AKAN has decreased by -61.27% in the past year. This is quite bad
The Revenue has been growing by 172.39% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)99.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.31%
Revenue 1Y (TTM)-61.27%
Revenue growth 3Y172.39%
Revenue growth 5YN/A
Sales Q2Q%97.47%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AKAN Yearly Revenue VS EstimatesAKAN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AKAN. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKAN Price Earnings VS Forward Price EarningsAKAN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKAN Per share dataAKAN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AKAN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKANDA CORP

NASDAQ:AKAN (12/4/2025, 8:03:55 PM)

Premarket: 1.24 +0.29 (+31.06%)

0.9461

-0.06 (-6.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-01 2022-11-01/bmo
Earnings (Next)12-13 2022-12-13/bmo
Inst Owners1.31%
Inst Owner Change-99.78%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap690.65K
Revenue(TTM)836.70K
Net Income(TTM)-4.10M
AnalystsN/A
Price TargetN/A
Short Float %20.41%
Short Ratio0.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.83
P/FCF N/A
P/OCF N/A
P/B 0.16
P/tB 0.16
EV/EBITDA N/A
EPS(TTM)-12.28
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-8.33
FCFYN/A
OCF(TTM)-5.45
OCFYN/A
SpS1.15
BVpS5.86
TBVpS5.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -51.76%
ROE -95.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 24.91%
FCFM N/A
ROA(3y)-148.92%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1486.96%
Cap/Sales 250.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 1.39
Altman-Z -11.56
F-Score5
WACC6.92%
ROIC/WACCN/A
Cap/Depr(3y)505.52%
Cap/Depr(5y)N/A
Cap/Sales(3y)97.76%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.31%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-61.27%
Revenue growth 3Y172.39%
Revenue growth 5YN/A
Sales Q2Q%97.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y55.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-304.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-165.25%
OCF growth 3YN/A
OCF growth 5YN/A

AKANDA CORP / AKAN FAQ

What is the fundamental rating for AKAN stock?

ChartMill assigns a fundamental rating of 1 / 10 to AKAN.


What is the valuation status for AKAN stock?

ChartMill assigns a valuation rating of 0 / 10 to AKANDA CORP (AKAN). This can be considered as Overvalued.


How profitable is AKANDA CORP (AKAN) stock?

AKANDA CORP (AKAN) has a profitability rating of 0 / 10.